Invivyd, Inc. (IVVD)

Market Cap	389.98M +216.5%
Revenue (ttm)	53.43M +110.5%
Net Income	-52.49M
EPS	-0.30
Shares Out	282.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,697,442
Open	1.470
Previous Close	1.450
Day's Range	1.370 - 1.475
52-Week Range	0.460 - 3.070
Beta	0.61
Analysts	Strong Buy
Price Target	8.75 (+534.06%)
Earnings Date	Mar 5, 2026

About IVVD

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 122
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://www.invivyd.com

Financial Performance

In 2025, Invivyd's revenue was $53.43 million, an increase of 110.47% compared to the previous year's $25.38 million. Losses were -$52.49 million, -69.11% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price target is $8.75, which is an increase of 534.06% from the latest price.

Price Target

$8.75

(534.06% upside)

Analyst Consensus: Strong Buy